his.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Cytoplasmic Relocalization of TAR DNA-Binding Protein 43 Is Not Sufficient to Reproduce Cellular Pathologies Associated with ALS In vitro.
AstraZeneca-Tufts Laboratory for Basic and Translational Neuroscience, Tufts University School of Medicine, Boston, United States.
IMED Biotech Unit, AstraZeneca Neuroscience IMED, AstraZeneca, Cambridge, United States.
AstraZeneca-Tufts Laboratory for Basic and Translational Neuroscience, Tufts University School of Medicine, Boston, United States.
University of Skövde, School of Bioscience. University of Skövde, The Systems Biology Research Centre. IMED Biotech Unit, AstraZeneca Discovery Science, Mölndal, Sweden. (Bioinformatik)ORCID iD: 0000-0003-2899-3801
Show others and affiliations
2017 (English)In: Frontiers in Molecular Neuroscience, ISSN 1662-5099, Vol. 10, 46Article in journal (Refereed) Published
Abstract [en]

Mutations in the gene TARDBP, which encodes TAR DNA-binding protein 43 (TDP-43), are a rare cause of familial forms of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). While the majority of mutations are found in the C-terminal glycine-rich domain, an alanine to valine amino acid change at position 90 (A90V) in the bipartite nuclear localization signal (NLS) of TDP-43 has been described. This sequence variant has previously been shown to cause cytoplasmic mislocalization of TDP-43 and decrease protein solubility, leading to the formation of insoluble aggregates. Since the A90V mutation has been described both in patients as well as healthy controls, its pathogenic potential in ALS and FTD remains unclear. Here we compare properties of overexpressed A90V to the highly pathogenic M337V mutation. Though both mutations drive mislocalization of the protein to the cytoplasm to the same extent, M337V produces more significant damage in terms of protein solubility, levels of pathogenic phosphorylation, and formation of C-terminal truncated protein species. Furthermore, the M337V, but not the A90V mutant, leads to a downregulation of histone deacetylase 6 and Ras GTPase-activating protein-binding protein. We conclude that in the absence of another genetic or environmental 'hit' the A90V variant is not sufficient to cause the deleterious phenotypes associated with ALS and FTD, despite prominent cytoplasmic protein relocalization of TDP-43.

Place, publisher, year, edition, pages
frontiers research foundation , 2017. Vol. 10, 46
Keyword [en]
TAR DNA-binding protein 43 (TDP-43), amyotrophic lateral sclerosis (ALS), frontotemporal dementia, mutation, neurodegenerative diseases, protein misfolding disease
National Category
Biochemistry and Molecular Biology
Research subject
Bioinformatics
Identifiers
URN: urn:nbn:se:his:diva-14041DOI: 10.3389/fnmol.2017.00046PubMedID: 28286471Scopus ID: 2-s2.0-85014051932OAI: oai:DiVA.org:his-14041DiVA: diva2:1136078
Available from: 2017-08-25 Created: 2017-08-25 Last updated: 2017-08-28Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMedScopus

Search in DiVA

By author/editor
Delsing, Louise
By organisation
School of BioscienceThe Systems Biology Research Centre
In the same journal
Frontiers in Molecular Neuroscience
Biochemistry and Molecular Biology

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 10 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf